金斯瑞Spike RBD蛋白詳情
| 類型 |
靶點 |
表達宿主 |
標簽 |
| 野生型 |
SARS-CoV-2 N protein |
Insect cell |
His |
| E.coli |
| SARS-CoV-2 S-RBD |
Insect cell |
His |
| Mammalian cell |
His/mFc |
| SARS-CoV-2 S-ECD |
Insect cell |
His/Flag |
| Mammalian cell |
| SARS-CoV-2 S1 |
Mammalian cell |
His |
| SARS-CoV-2 RBD-sc-dimerNew
|
Mammalian cell |
/ |
N Protein：核衣殼蛋白全長，序列由金斯瑞設計并優化。
下游應用：體外診斷抗體制備，體外診斷試劑盒生產。
S-RBD：S蛋白受體結合區，序列由金斯瑞設計，結合蛋白3D構象分析，預測更準確。
下游應用：功能檢測，中和抗體制備，體外診斷試劑盒生產。
S-ECD：S蛋白膜外區全長。
下游應用：功能檢測，體外診斷抗體制備。
S RBD-sc-dimer：RBD結構域中由二硫鍵鏈接二聚體。
下游應用：在MERS，SARS，COVID-19中均可構建RBD-sc-dimer結構，可用于MERS，SARS，COVID-19等疫苗制備。
| 靶點 |
應用 |
純度 |
QC |
| S-RBD His tag |
IgM/IgG kit with Anti-His antibody |
>90% |
SDS-PAGE, WB,
ELISA binding against ACE2 |
| S-RBD mFc tag |
IgM/IgG kit with Anti-Mouse antibody |
Spike RBD蛋白，His tag
Lane M1: Protein Marker, GenScript, Cat. No. M00516
Lane M2: Protein Marker, GenScript, Cat. No. M00521
Lane 1: BSA (2.00 μg)
Lane 2: RBD Protein (Reducing condition, 2.00 μg)
Lane 3: RBD Protein (Non-reducing condition, 2.00 μg)
Lane 4: RBD Protein (Reducing condition)
Lane 5: RBD Protein (Non-reducing condition)
Primary antibody: Mouse-anti-His mAb (GenScript, Cat.No. A00186)
金斯瑞生產的S-RBD（his tag）蛋白SDS-PAGE純度>90%，純度高。
采用ELISA方法檢測S-RBD（his tag）蛋白與ACE2的結合活性，EC50<100ng/ml，活性好。
TCR-抗原親和性和免疫原性篩選
個性化癌癥疫苗（PCV）
個性化疫苗藥效篩選
采用ELISA方法檢測3個不同批次的S-RBD（his tag）蛋白與ACE2的結合活性，3個批次蛋白活性基本一致。
Spike RBD蛋白，mFc tag
Lane M1: Protein Marker, TaKaRa, Cat. No. 3452
Lane M2: Protein Marker, GenScript, Cat. No. M00521
Lane 1: Reducing condition
Lane 2: Non-reducing condition
Lane P: Mouse IgG1, Kappa (Sigma, Cat.No.M9269) as a positive
control
Primary antibody: MonoRab? Mouse IgG (76F10), mAb, Rabbit (GenScript,
Cat.No. Cat. V90301)
金斯瑞生產的S-RBD（mFc tag）蛋白SDS-PAGE純度>90%，純度高。
采用ELISA方法檢測S-RBD（mFc tag）蛋白與ACE2的結合活性，EC50<100ng/ml，活性好。
Spike RBD-sc-dimer蛋白
注：Lane M: Merker
Lane 1: Reducing condition
Lane 2: Non-reducing condition
金斯瑞生產RBD-sc-dimer，SDS-PAGE檢測純度達90%，SEC-HPLC測試純度達97.9%，純度高。
采用ELISA方法檢測RBD-sc-dimer與ACE2蛋白結合活性，EC50低至16.8ng/ml，活性高。
Lianpan Dai, Tianyi Zheng, Kun Xu, A universal design of
betacoronavirus vaccines against COVID-19, MERS and SARS.Cell.August,6,2020.
